Risk Factors ofMultidrug-ResistantBacteria in LowerRespiratory Tract Infections: A Systematic Review and Meta-Analysis

Background. Multidrug-resistant (MDR) bacteria are the main cause of lower respiratory tract infections (LRTIs) with high mortality. *e purpose of this study is to identify the risk factors associated with MDR by performing a systematic review and meta-analysis. Methods. PubMed, EMBASE (via Ovid), and Cochrane Library were systematically searched for studies on the risk factors for MDR bacteria in LRTIs as of November 30, 2019. Literature screening, data abstraction, and quality assessment of the eligible studies were performed independently by two researchers. Results. A total of 3,607 articles were retrieved, of which 21 articles representing 20 cohort studies published in English were included after title/abstract and full-text screening. Among the 21 articles involving 7,650 patients and 1,360MDR organisms, ten reported the risk factors forMDRGram-positive bacteria (GPB) and Gram-negative bacteria (GNB), ten for MDRGNB, and one forMDRGPB.*emeta-analysis results suggested that prior antibiotic treatment, inappropriate antibiotic therapy, chronic lung disease, chronic liver disease and cerebral disease, priorMDR and PA infection/colonization, recent hospitalization, longer hospitalization stay, endotracheal tracheostomy and mechanical ventilation, tube feeding, nursing home residence, and higher disease severity score were independent risk factors for MDR bacteria. Conclusions. *is review identified fourteen clinical factors that might increase the risk of MDR bacteria in patients with LRTIs. Clinicians could take into account these factors when selecting antibiotics for patients and determine whether coverage for MDR bacteria is required. More well-designed studies are needed to confirm the various risk factors for MDR bacteria in the future.

[1]  Wei Zhu,et al.  Risk factors for carbapenem-resistant Klebsiella pneumoniae infection relative to two types of control patients: a systematic review and meta-analysis , 2020, Antimicrobial Resistance & Infection Control.

[2]  Roger Williams,et al.  Antimicrobial resistance in chronic liver disease , 2019, Hepatology International.

[3]  M. Ip,et al.  Antibiotic-Resistant Community-Acquired Bacterial Pneumonia. , 2019, Infectious disease clinics of North America.

[4]  R. Wunderink,et al.  Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community‐acquired pneumonia , 2019, Respirology.

[5]  Tiantuo Zhang,et al.  Differences in microbial etiology between hospital-acquired pneumonia and ventilator-associated pneumonia: a single-center retrospective study in Guang Zhou , 2019, Infection and drug resistance.

[6]  M. Scott,et al.  A nonlinear time-series analysis approach to identify thresholds in associations between population antibiotic use and rates of resistance , 2019, Nature Microbiology.

[7]  H. Van Vlierberghe,et al.  Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. , 2019, Gastroenterology.

[8]  Zhao Zhang,et al.  Molecular Epidemiology and Risk Factors of Ventilator-Associated Pneumonia Infection Caused by Carbapenem-Resistant Enterobacteriaceae , 2019, Front. Pharmacol..

[9]  Eyal Oren,et al.  Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet. Infectious diseases.

[10]  Mohammad Hossein Khosravi,et al.  Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[11]  N. Bhattarai,et al.  Incidence and outcomes of multidrug-resistant gram-negative bacteria infections in intensive care unit from Nepal- a prospective cohort study , 2018, Antimicrobial Resistance & Infection Control.

[12]  Xuan Sun,et al.  Risk factors for multidrug‐resistant Gram‐negative bacteria infection in intensive care units: A meta‐analysis , 2018, International journal of nursing practice.

[13]  Yee-Chun Chen,et al.  Risk for subsequent infection and mortality after hospitalization among patients with multidrug-resistant gram-negative bacteria colonization or infection , 2018, Antimicrobial Resistance & Infection Control.

[14]  Ying Luan,et al.  Pathogenic bacterial profile and drug resistance analysis of community-acquired pneumonia in older outpatients with fever , 2018, The Journal of international medical research.

[15]  W. Rodriguez-Cintron,et al.  Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients , 2018, European Respiratory Journal.

[16]  G. Raman,et al.  Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis , 2018, Antimicrobial Resistance & Infection Control.

[17]  W. Guan,et al.  Antibiotic-resistant Pseudomonas aeruginosa infection in patients with bronchiectasis: prevalence, risk factors and prognostic implications , 2018, International journal of chronic obstructive pulmonary disease.

[18]  Hyung Koo Kang,et al.  Proposed risk factors for infection with multidrug-resistant pathogens in hemodialysis patients hospitalized with pneumonia , 2017, BMC Infectious Diseases.

[19]  P. Ji,et al.  Trends and relationship between antimicrobial resistance and antibiotic use in Xinjiang Uyghur Autonomous Region, China: Based on a 3 year surveillance data, 2014-2016. , 2017, Journal of infection and public health.

[20]  E. Snitkin,et al.  Network of microbial and antibiotic interactions drive colonization and infection with multidrug-resistant organisms , 2017, Proceedings of the National Academy of Sciences.

[21]  M. Samore,et al.  Attributable Mortality of Healthcare-Associated Infections Due to Multidrug-Resistant Gram-Negative Bacteria and Methicillin-Resistant Staphylococcus Aureus , 2017, Infection Control & Hospital Epidemiology.

[22]  Ziwen Zhao,et al.  Pneumonia caused by extensive drug-resistant Acinetobacter baumannii among hospitalized patients: genetic relationships, risk factors and mortality , 2017, BMC Infectious Diseases.

[23]  A. Torres,et al.  Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance. , 2017, The Journal of infection.

[24]  M. Bassetti,et al.  The management of multidrug-resistant Enterobacteriaceae , 2016, Current opinion in infectious diseases.

[25]  B. Kocić,et al.  Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10‐year study , 2016, Journal of clinical pharmacy and therapeutics.

[26]  G. Guyatt,et al.  Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies , 2016, British Medical Journal.

[27]  Jung-San Chang,et al.  An antibiotic decision-making tool for patients with pneumonia admitted to a medical intensive care unit. , 2016, International journal of antimicrobial agents.

[28]  Peggy Cruse,et al.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Tim Friede,et al.  Meta‐analysis of two studies in the presence of heterogeneity with applications in rare diseases , 2016, Biometrical journal. Biometrische Zeitschrift.

[30]  Marcus D. Ruopp,et al.  Respiratory Tract Infection Clinical Trials from 2007 to 2012. A Systematic Review of ClinicalTrials.gov. , 2015, Annals of the American Thoracic Society.

[31]  A. Großhennig,et al.  No solution yet for combining two independent studies in the presence of heterogeneity , 2015, Statistics in medicine.

[32]  Z. Memish,et al.  Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options , 2014, Lancet. Infectious Diseases (Print).

[33]  T. V. Van Schooneveld,et al.  Epidemiology and Predictors of Multidrug-Resistant Community-Acquired and Health Care-Associated Pneumonia , 2014, Antimicrobial Agents and Chemotherapy.

[34]  George F Borm,et al.  The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method , 2014, BMC Medical Research Methodology.

[35]  A. Kaya,et al.  Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes. , 2014, American journal of infection control.

[36]  Jian-hui Chen,et al.  Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia. , 2013, American journal of infection control.

[37]  Hong-tao Xu,et al.  Prevalence and clinical prognosis of heteroresistant vancomycin-intermediate Staphylococcus aureus in a tertiary care center in China. , 2013, Chinese medical journal.

[38]  A. Costa-Pereira,et al.  Additional risk factors for infection by multidrug-resistant pathogens in healthcare-associated infection: a large cohort study , 2012, BMC Infectious Diseases.

[39]  A. Péchinot,et al.  Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia , 2012, Intensive Care Medicine.

[40]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[41]  W. Wang,et al.  Risk factors for pneumonia caused by multidrug‐resistant Gram‐negative bacilli among liver recipients , 2010, Clinical transplantation.

[42]  M. J. Pozuelo,et al.  Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. , 2010, Diagnostic microbiology and infectious disease.

[43]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[44]  M. Maciá,et al.  Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  Maarten Bekaert,et al.  Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia , 2008, Critical care.

[46]  古谷 良輔,et al.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.

[47]  S. Nseir,et al.  Prevalence and outcome of severe chronic obstructive pulmonary disease exacerbations caused by multidrug-resistant bacteria , 2008, Current opinion in pulmonary medicine.

[48]  Jill Hayden,et al.  Evaluation of the Quality of Prognosis Studies in Systematic Reviews , 2006, Annals of Internal Medicine.

[49]  P. Hsueh,et al.  Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991–2003 at a university hospital in Taiwan , 2005, International Journal of Antimicrobial Agents.

[50]  D. Gu,et al.  A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study. , 2018, The Lancet. Infectious diseases.

[51]  Peter A. Alces,et al.  Reinventing the wheel? , 2009, The Lancet. Oncology.